Medicine and Dentistry
Analysis
20%
Cancer
15%
Cancer of Unknown Primary Origin
8%
Cancer Registry
7%
Cancer Treatment
7%
Carcinoid
34%
Carcinoid Syndrome
27%
Cells
7%
Colon
5%
Consensus
13%
Development
6%
Diagnosis
16%
Diarrhea
9%
Diseases
12%
Drug Megadose
10%
Evaluation
12%
Experience
21%
Gallium 68
9%
Gastroenteropancreatic Neuroendocrine Tumor
10%
Immune Checkpoint Inhibitor
17%
Immunity
11%
Incidence
6%
Indium 111
18%
Large Cell Neuroendocrine Carcinoma
19%
Liver
8%
Malignant Neoplasm
18%
Movement
9%
Neoplasm
29%
Neuroendocrine Tumor
62%
Octreotide
10%
Oncology
8%
Pancreas Adenocarcinoma
9%
Patient
100%
Pentetreotide
15%
Pentetreotide in 111
6%
Peptide
10%
Positron Emission Tomography-Computed Tomography
9%
Quality of Life
6%
Radiation Therapy
16%
Rectum
5%
Somatostatin
6%
Somatostatin Derivative
23%
Somatostatin Receptor
10%
Standardized Uptake Value
9%
Surgery
13%
Survival
12%
Symptom
15%
Therapeutic Procedure
65%
Therapeutics
9%
Toxicity
11%
Pharmacology, Toxicology and Pharmaceutical Science
5 Hydroxyindoleacetic Acid
6%
Acromegaly
8%
Adverse Event
8%
Angiopeptin
7%
Anticarcinogen
5%
Antiemetic Agent
6%
Apoptosis
8%
Blindness
8%
Cancer of Unknown Primary Site
14%
Carcinoid
23%
Carcinoid Syndrome
49%
Chemotherapy
21%
Clinical Study
7%
Clinical Trial
13%
Colorectal Carcinoma
6%
Diarrhea
27%
Digestive System Cancer
5%
Disease
18%
Everolimus
5%
Gastroenteropancreatic Neuroendocrine Tumor
19%
Immune Checkpoint Inhibitor
12%
Immunotherapy
6%
Incidence
6%
Indium 111
22%
Irinotecan
5%
Malignant Neoplasm
32%
Mammalian Target of Rapamycin Inhibitor
6%
Nausea and Vomiting
5%
Neoplasm
28%
Neuroendocrine Tumor
72%
Octreotide
60%
Pentetreotide
20%
Pentetreotide in 111
11%
Peptide
20%
Pharmacokinetics
10%
Placebo
10%
Polyethylene Terephthalate
6%
Radioisotope
16%
Radiosensitizing Agent
8%
Receptor
13%
Side Effect
5%
Somatostatin
18%
Somatostatin Derivative
49%
Somatostatin Receptor
13%
Survival
16%
Symptom
22%
Telotristat Ethyl
15%
Tolerability
5%
Toxicity
20%
Zofran
9%